Home | Publications | Country | Latin America | Chile place holder
place holder place holder

Chile

The Pharmaceutical Market: Chile


Publication Date   March 2007
Publisher   Espicom
Product Type   Strategic Report
Pages   120
ISBN Number   not applicable
Product Code   ESP561
Ask a question about this product?

Price £595.00

approximately: $1,178 | €756

Summary


During the last five years, Chile has successfully overcome an economic crisis. Continuous reforms have guaranteed and raised living standards of its 16 million population over neighbouring countries, although unemployment remains high, at nearly 10%. GDP is expected to grow by 5.9% in real terms in 2005, reaching US$100.7 billion, equal to US$6,243 per capita. Trade liberalisation and investment opportunities are also key to Chile's success, fuelled by trade agreements with the EU, the US-Chile FTA, the Korea-Chile FTA and the Trans-Pacific SEP. Trade agreements with China and India are in progress.

The health profile in Chile faces the traditional problems of poverty, poor environmental conditions and infectious diseases, associated with developing countries, together with other problems more associated with the developed world, including an ageing population and chronic illnesses. However, inequalities remain between rural & urban and poor & rich areas. For instance, infant mortality varies from two deaths per thousand population in urban and rich areas, to over 34 in less controlled areas. Life expectancy in the country is among the highest in the region, at an average of 77.7 years in 2004.

Equity, participation, solidarity and quality are the four pillars of the Chilean Healthcare Planning Objectives between 2000 and 2010. This is a major step to strengthen a more preventive and universal primary care system, to enforce and expand the programme AUGE to 56 ailments by 2007, and to improve IT health systems and management & auditing needs. The goals for 2010 are to increase health equities, meet the needs of the ageing population, face sociological changes, service an 'empowered' population and continue to enhance sanitary surveillance.

The Chilean pharmaceutical market is the sixth largest market in the region, after Mexico, Brazil, Argentina, Venezuela and Colombia. The pharmacy sector was valued at US$698.5 million at manufacturers' prices in 2004. LabChile was the leading producer, with sales estimated at US$53.6 million, equal to 8.0% of the sector. Other leading producers included Recalcine (7.1%), Saval (6.5%) and Andrmaco (4.5%). On 24 th March 2005, Andrmaco acquired Silesia and its subsidiaries, taking the third position. GMP standards are expected to be met in full by the end of 2005, and bioequivalence will be performed on 16 selected active ingredients between 2005 and 2009. This might enhance pharmaceutical exports.

These pharmaceutical market reports are ideal for executives wanting to understand the key drivers in pharmaceutical markets and have access to a wealth of statistical data. Each report opens with an outlook section that provides analysis of the market, 5-year market forecasts, national data projections, market outlook and key developments such as regulation, pricing/reimbursement, intellectual property, health facilities and government policy. The report also provides extensive background information, population trends, health status, health expenditure, organisation & administration, hospital services, medical personnel, healthcare development, market access information, trade data for raw materials and finished products and essential industry contacts. Included with the report are 3 free quarterly updated outlook reports, enabling you to keep up to date with market developments for a year.

Content


Background Data

  • Geography
  • Political Overview
  • Economic Overview
    • GDP,
  • Population
    • Projected Population,
    • Population by Region, 2002 Census
    • Projected Population by Age,
    • Projected Population by Age, 1975-2025 (%)
  • Demographic Indicators
    • Demographic Indicators,
  • Mortality
    • Selected Causes of Death,
    • Selected Causes of Death by Sex,
    • Selected Specific Causes of Death,
    • Infant Mortality
    • Infant Deaths by Cause,
  • Morbidity
    • Reported and Cumulative Cases of Selected Infectious Diseases,
    • HIV/AIDS
    • Reported AIDS Cases,
    • Estimated AIDS & HIV Cases,
  • Charts
    • Map of Chile
    • Population by Age, 1975-2025 (%)
    • Selected Causes of Death,
    • Chichester, West Sussex, PO20 2FS, United Kingdom

Healthcare System

  • Organisation & Administration
    • Health Beneficiaries,
    • SNSS / FONASA
    • Isapres
    • Isapres' Beneficiaries,
    • Beneficiaries by Isapre Type,
    • The Reform
    • SWOT Analysis of the Chilean Health System,
    • Major Structural Implementations,
    • The Five-Law Reform Bill,
    • AUGE Pilot Programme Patients, August 2002-Isapres' Solvency Bill,
  • Health Expenditure
    • Health Expenditure, 1998-2003 (US$ Billion)
    • Health Expenditure, 1998-2003 (%)
    • Public Health Expenditure
    • Public Health Expenditure,
    • Public Health Expenditure by Source of Income, 1990-2005 (%)
    • Isapres' Health Expenditure
    • Isapres' Operational Revenues,
    • Isapres' Balance Sheet,
  • Hospital Services
    • Hospital Resources
    • Hospitals by Provider,
    • Hospital Beds by Provider,
    • Hospital Beds by Region & Provider,
    • Hospital Activity
    • Hospital Discharges,
    • Hospital Activity by Provision & Insurance Affiliation, 2000 (%)
    • Hospital Discharges by Cause,
    • SNSS Hospital Indicators,
    • SNSS Hospital Activity,
    • Free Election System Activity,
    • Free Election System Activity by Type of Treatment,
    • Isapres Activity, 1990-2002 (000s)
    • Isapres Activity by Type of Treatment, 2001-2002 (000s)
    • Isapres' Discharges by Cause, 2001 (000s)
  • Chile Healthcare System
    • Hospital Investments
    • Hospital Investments, 2003-2007 (Million Pesos)
    • Hospital Investment Projects,
    • Projects for PPA Funding, 2004 (Million Pesos)
    • Areas for PPA Funding,
  • Ambulatory Care
    • SNSS Outpatient Facilities,
    • Medical Consultations by Programme,
    • Medical Treatment by Type, Place of Treatment & Health Insurance, 2000 (%)
  • Medical Personnel
    • Doctors by Specialty,
    • Doctors by Age Group & Sex,
    • Doctors by Regional Council & Sex,
    • SNSS Personnel,
  • Charts
    • Reformed Functional Organisation
    • Isapres' Beneficiaries,
    • Beneficiaries by Isapre Type, 2006 (%)
    • Private Health Expenditure by Source of Funding, 2000-2003 (%)
    • Public Health Expenditure by Source of Income, 1990-2005 (%)
    • Isapres' Operational Revenues,
    • Isapres' Balance Sheet, 2005 (%)
    • Hospitals by Provider,
    • Hospital Beds by Provider,
    • Hospital Beds by Region, 2003 (Rate per 1,000 Population)
    • Doctors,
    • Selected SNSS Medical Personnel,
    • Chichester, West Sussex, PO20 2FS, United Kingdom
  • Accessing The Pharmaceutical
  • Market

Accessing The Pharmaceutical Market

  • Introduction
  • Regulatory Environment
    • Registration
    • Number of Product Registrations,
    • Quality Standards
    • Stock Control
    • Legal Proceedings
    • Advertising
    • Patent Protection & Intellectual Property Rights
    • Pharmaceutical Patent Applications
    • Cumulative Pharmaceutical Applications, September 1991- April
    • Pricing
    • Reimbursement
  • Distribution Channels
    • Pharmacy Own-Labelled Production
    • Retail Pharmacy Chains
    • Cruz Verde
    • Farmacias Ahumada
    • Farmacias SalcoBrand
    • FarmaLider
  • Cenabast
  • Trade Fairs
  • Exposalud
  • Domestic Production
    • Trade Associations
  • Asilfa
  • Asilfa's Members,
  • Cameved
  • Canalab
  • Canalab's Members,
    • CIF
    • CIF's Members,
    • Domestic Producers
    • Andrmaco
    • Financial Indicators
    • Andrmaco's Sales, 2000-2005 (Billion Pesos)
    • Product Portfolio
    • Manufacturing Capabilities
  • Chile Accessing The Pharmaceutical Market
    • Exports
    • International Divisions
    • Bag
    • Financial Indicators
    • Product Portfolio
    • Manufacturing Capabilities
    • Exports
    • Bestpharma
    • Product Portfolio
    • Biosano
    • Financial Indicators
    • Product Portfolio
    • Biosano's Product Portfolio,
    • Manufacturing Capabilities
    • LabChile
    • Financial Indicators
    • Product Portfolio
    • Manufacturing Capabilities
    • Exports
    • Distribution
    • Labomed
    • Pharmaceutical Producers Represented by Labomed,
    • Maver
    • Mintlab
    • Recalcine
    • Financial Indicators
    • Product Portfolio
    • Manufacturing Capabilities
    • Sanderson
    • Financial Indicators
    • Product Portfolio
    • Manufacturing Capabilities
    • Exports
    • Saval
    • Financial Indicators
    • Product Portfolio
    • Manufacturing Capabilities
    • Exports
    • Research & Development
  • Directory

Accessing The Pharmaceutical Market

  • Government Organisations
  • Trade Associations
  • Charts
    • Drug Pricing by Product Type, 2002-2005 (US$)
    • Pharmacy Sector by Distribution Channels, 2006 (%)
    • FASA's Sales,
    • Andrmaco's Sales,
    • Saval's Sales,